Immunoglobulin News and Research

RSS

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

AIM suppression could help prevent obesity-associated diseases

Obesity is linked to the widespread epidemics of diabetes and heart disease that plague society, but a lesser-known fact is that the weight can also lead to autoimmune disease.

5 Apr 2013

Novel cell therapy effective in treating aggressive form of childhood leukemia

Two children with an aggressive form of childhood leukemia had a complete remission of their disease—showing no evidence of cancer cells in their bodies—after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells.

26 Mar 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that the first patient enrolled in the pivotal Phase III clinical study of its RI-002 has been dosed.

7 Mar 2013

Excess of vitamin D during pregnancy can increase risk of food allergy in children

Pregnant women should avoid taking vitamin D supplements. Substitution appears to raise the risk of children developing a food allergy after birth.

28 Feb 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

C-section babies more likely to develop allergies

For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two.

25 Feb 2013

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.

18 Feb 2013

Age not a major factor in asthma allergic sensitization rates

Results from a US study suggest that there is no significant difference in allergic sensitization rates between younger and older patients with asthma.

18 Feb 2013

Individualized flu immune responses revealed by high-throughput sequencing

Researchers have shown that it is possible to create personalized, individual-specific measurements of the antibody repertoire in response to influenza vaccination using high-throughput DNA sequencing technology.

11 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013